← Back to Search

CAR T-cell Therapy

CTX130 for Kidney Cancer

Phase 1

Waitlist Available

Research Sponsored by CRISPR Therapeutics AG

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥18 years and body weight ≥42 kg

Karnofsky performance status (KPS) ≥80%

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from ctx130 infusion up to 60 months post-infusion]

Awards & highlights

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective in treating kidney cancer that has come back or does not respond to treatment.

Who is the study for?

This trial is for adults over 18 with a weight of at least 42 kg who have kidney cancer that's gotten worse or hasn't responded to treatment. They must be able to perform daily activities well (KPS ≥80%) and agree to use contraception for a year post-treatment. People can't join if they've had organ transplants, previous CAR T cell therapy, certain severe health conditions, are pregnant/breastfeeding, have untreated HIV/hepatitis infections, or other active cancers.Check my eligibility

What is being tested?

The study is testing CTX130's safety and effectiveness in treating renal cell carcinoma that has relapsed or doesn't respond anymore. It's an early-phase trial where all participants receive the same experimental therapy without any comparison group.See study design

What are the potential side effects?

While specific side effects of CTX130 aren't listed here, similar therapies often cause immune reactions, fatigue, possible organ inflammation due to immune response, and increased risk of infection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years or older and weigh at least 42 kg.

Select...

I am mostly able to carry out normal activities without assistance.

Select...

My kidney cancer cannot be surgically removed and has not responded to standard treatments.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from ctx130 infusion up to 60 months post-infusion]

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from ctx130 infusion up to 60 months post-infusion]

This trial's timeline: 3 weeks for screening, Varies for treatment, and from ctx130 infusion up to 60 months post-infusion] for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Part A (dose escalation): Incidence of adverse events

Part B (cohort expansion): Objective response rate

Secondary outcome measures

Overall Survival

Progression Free Survival

Trial Design

1Treatment groups

Experimental Treatment

Group I: CTX130Experimental Treatment1 Intervention

Administered by IV infusion following lymphodepleting chemotherapy.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

CRISPR Therapeutics AGLead Sponsor

8 Previous Clinical Trials

785 Total Patients Enrolled

Matthias Will, MDStudy DirectorCRISPR Therapeutics

3 Previous Clinical Trials

162 Total Patients Enrolled

Anjali Sharma, MDStudy DirectorCRISPR Therapeutics

1 Previous Clinical Trials

45 Total Patients Enrolled

Media Library

CTX130 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04438083 — Phase 1

Kidney Cancer Research Study Groups: CTX130

Kidney Cancer Clinical Trial 2023: CTX130 Highlights & Side Effects. Trial Name: NCT04438083 — Phase 1

CTX130 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04438083 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many places are overseeing this clinical experiment?

"This trial is currently running in 5 different areas, such as Houston's Research Site 4 and Salt Lake City's Research Site 3. Additionally, there are other research sites located in Toronto and various other places."

Answered by AI

Are there any vacancies remaining in this clinical exploration?

"Correct. The details available on clinicaltrials.gov suggest that this medical trial is actively recruiting participants, with a total of 107 patients needed among 5 different sites. This research was first published on June 16th 2020 and updated most recently on May 16th 2022."

Answered by AI

How many participants are currently being monitored in this clinical research?

"The sponsor for this clinical trial, CRISPR Therapeutics AG, requires a total of 107 eligible patients to complete the study. This will be done at two primary locations: Research Site 4 in Houston and Research Site 3 in Salt Lake City."

Answered by AI

Has CTX130 been given the green light by the FDA?

"The safety of CTX130 is estimated to be a 1 on the scale due to its status as an early-phase trial, and thus there is only scant evidence supporting efficacy and security."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

2020. "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04438083.

All > Renal Cell Carcinoma